Notable Labs announced the advancement of its volasertib Phase 2 program utilizing PPMP to enrich the study population for clinical responders. Notable is developing its lead drug asset volasertib with its proprietary PPMP for patients with relapsed/refractory acute myelogenous leukemia (r/r AML). “PPMP’s recently reported, 100% accurate prediction of fosciclopirox’s clinical trial outcome has allowed us to eliminate an entire 30-patient cohort from the planned volasertib program,” said Thomas A. Bock, MD, MBA, Chief Executive Officer of Notable Labs. “This further validates our PPMP-guided development strategy to target responding patients, improve patient outcomes and reduce the risk, time, and cost of drug development.” More information at https://lnkd.in/e7UkBsBP. #fosciclopirox #PPMP #drugdevelopment #hematology #hematologists #bloodcancer #precisionmedicine #leukemia #AML #MDS #cancerresearch
Congratulations!!!
Director of Business Operations @ Inscripta, Inc. | Operations, Process Improvement
5moCongrats team!